Dendreon and Cell Therapeutics - Starting Strong in 2012
The Paragon Report Provides Equity Research on Dendreon Corporation & Cell Therapeutics
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 01/17/12 -- Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big drug launches, FDA hearings, and greater M&A activity in the coming months. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:
J.P. Morgan's Healthcare Conference in San Francisco this month offered an appealing venue for biotechs to target potential deals in 2012. According to Henry Gosebruch, managing director of health-care mergers and acquisitions at JPMorgan Chase & Co, the analyst firm expects "the large biotechs to be active acquirers in 2012." Gosebruch added that "investors have rewarded strategic acquisitions that enhance long-term growth and companies that continue their history of developing innovative therapies, as opposed to turning into dividend- paying, share-repurchase type low-growth stocks."
According to a recent report from Bloomberg, biotech companies have historically been less active than their pharmaceutical industry counterparts regarding M&A activity. For example, over the past 4 years, Bristol-Myers has completed an impressive 17 acquisitions, while biotech industry heavyweight, Celgene, has completed a mere 3 acquisitions.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Earlier this month, Dendreon Corporation helped drive shares of the biotechnology industry higher after the company said sales of its prostate-cancer therapy Provenge continued to grow in the fourth quarter. Sales of Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer, rose 25 percent compared to the third quarter. A round of treatment with Provenge costs $93,000, and Medicare conducted a long review of the drug before deciding to cover it in June, the Associated Press reports.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2012 - 07:20 Uhr
Sprache: Deutsch
News-ID 1073436
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 65 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dendreon and Cell Therapeutics - Starting Strong in 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
